Table II.
Thermo-Responsive Polymers and Their Applications
| Polymer | Drug delivery and other biomedical applications | References |
|---|---|---|
| P(NIPAAm) copolymers | ||
| Poly(NIPAAm-co-DMAAm-co-AMA)-b-PUA | Doxorubicin and folic acid | (55) |
| Poly(HEMA-g-NIPAAm) | Theophylline and insulin | (56) |
| Poly(NIPAAm)-g-HA | Post-surgical tissue adhesions | (57) |
| Poly(NIPAAm)-g-gelatin | Hemostatic aid during surgery | (57) |
| PEG/PLGA block copolymers | ||
| PLGA-b-PEG-b-PLGA triblock copolymers | Delivery of proteins (lysozymes) | (34) |
| PLGA–PEG–PLGA triblock copolymers | Testosterone | (58) |
| PEG-b-PLGA-b-PEG triblock copolymers | In situ generated implants | (59) |
| Poly(organophosphazenes) | ||
| Poly(organophosphazene) hydrogel | Doxorubicin | (60) |
| Poly(organophosphazene) hydrogel | Dextran and albumin | (61) |
| PEG/biodegradable polyester copolymers | ||
| Poly(N-HPMAmDL-b-PEG) | Paclitaxel | (62) |
| PEG and PPG | In situ generated implants | (63) |
| PLLA/PEG/PLLA | Doxorubicin | (64) |
| PEO/PPO block copolymers | ||
| Pluronic® F127 (PEO99–PPO67–PEO99) | Metronidazole and methylene blue | (65) |
| Crosslinked PEO–PPO | In situ generated implants | (63) |
| Pluronic® F127 | In situ implant (hGH) | (66) |
DMAAm dimethylacrylamide, PCL poly(caprolactone), PLLA poly(l-lactic acid), P(NIPAAm) poly(N-isopropylacrylamide), PPO poly(propylene oxide), PLGA poly(d,l-lactide-co-glycolic acid), HPMAmDL 2-hydroxypropyl methacrylamide lactate, HEMA hydroxyethyl methacrylate, PEO poly(ethylene oxide), PEG poly(ethylene glycol), PPG poly(propylene glycol), HA hyaluronan, hGH human growth hormone